Business Wire

CA-JUNIPER-NETWORKS

12.12.2023 08:01:36 CET | Business Wire | Press release

Share
DNA Plc Automates New Data Centers with Juniper Networks® and NEC

Juniper Networks® (NYSE: JNPR), a leader in secure, AI-driven networks, and NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, today announced that DNA, part of Telenor Group and one of Finland’s leading mobile and fixed communications service providers, has deployed an intent-based networking data center fabric based on Juniper’s innovative automation software plus high-performance hardware and utilizing NEC’s advanced systems integration expertise. DNA’s new data center infrastructure provides a unified platform for both its business-to-business customer services and internal IT services. Additionally, Juniper Networks™ QFX Series Switches were chosen to power DNA’s Telco Cloud sites across Finland.

The overall objective for DNA’s data center infrastructure refresh is to enable new revenue-generating services whilst delivering operational efficiencies, together leading to enhanced user experiences. By automating the data center network, DNA can eliminate human error, optimize its technical team’s workload to focus on service creation and simplify first-class service delivery at scale. QFX switches enable low latency networking with high reliability and capacity, the key requirements for delivering various services to mobile users who are looking for high-performance network quality.

Juniper Apstra System: Intent-based Networking

  • DNA has selected the Juniper Apstra solution as the data center infrastructure’s foundation: unique, intent-based networking software that simplifies, automates and validates data center design, planning and operations, from Day 0 to Day 2+.
  • Apstra is a turnkey multi-vendor automation solution (both hardware- and OS-agnostic), that provides DNA with a unified, real-time view of millions of data center elements, plus their dynamic performance, relationships and interdependencies.
  • Apstra’s capabilities bring agility and more reliability to DNA’s network design, build and operations. The entire network management operations will be streamlined, and IT teams will be able to focus more on other priorities.
  • With Apstra, DNA can create a set of templates for its data center network built on its desired intent and required business outcomes. Apstra automatically converts this intent into the network configurations and policies necessary to consistently achieve DNA’s defined outcomes.
  • The Apstra-enabled network undergoes continuous, closed-loop assurance and self-validation to ensure compliance with the declared intent from the blueprint.
  • Using the operational, real-time analytics it constantly generates, Apstra is also able to deliver much faster and highly-accurate root-cause analysis of network issues and mitigation data, helping DNA to maximize its data center and services uptime.
  • DNA also deployed Juniper Networks QFX Series Switches across its new data center fabric. The QFX Series complements Apstra in DNA’s network by delivering industry-leading reliability, performance and scalability.
  • NEC is the strategic partner for DNA, providing pre-integration consultancy and validation as well as premium level support for Juniper’s solution, leveraging its expert support team of certified engineers.

Supporting Quotes:

“DNA has always been an innovator, using the best technology available to provide new services and better experiences for our customers. Because Finnish businesses are fully committed to digital transformation, and their expectations of our service reliability and quality are extremely high, we knew that we had to up our game in the data center by deploying state-of-the-art automation and networking technology. By working with Juniper and NEC, DNA is able to deliver those first-class user experiences and maintain our reputation.”

- Pekka Jääskeläinen, Vice President, Core & IP Networks, DNA Plc

“As a long-standing partner to the Telenor Group, NEC is honored to help DNA drive higher efficiency, agility, and availability of its data center network with automated solutions alongside our strategic partner Juniper. Based on our wealth of multi-vendor, multi-domain network systems integration capability and best-of-breed ecosystem, provided by NEC’s Center of Excellence (CoE), we will continue delivering transformative networking solutions and services that overcome increasing business challenges and keep our customers ahead of the curve.”

- Masayuki Kayahara, General Manager, Service Provider Solutions Department, NEC

“Apstra helps to de-risk data center networking significantly but also streamlines the operational overhead, making life much easier for pressured operators. Automation drives down the total cost of ownership in DNA’s data centers and frees up talent, all the while enabling it to open up rich new revenue streams via services which can be taken to market quickly and more reliably.”

- Mansour Karam, Group Vice President Products, Cloud Ready Data Center, Juniper Networks

Additional Resources

Blog: DIY Network Automation – a High-cost Operation for Telecom Data Centers
Research Topic: What is Intent-based Networking?
Infographic: The State of Data Center Network Automation

About Juniper Networks

Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on X (formerly Twitter), LinkedIn and Facebook.

Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at http://www.nec.com.

LinkedIn: https://www.linkedin.com/company/nec/
YouTube: https://www.youtube.com/user/NECglobalOfficial
Facebook: https://www.facebook.com/nec.global/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231206095386/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye